Aripiprazole and Tourette syndrome

Dear Editor,

Tourette syndrome (TS) is characterized by chronic motor and vocal tics. In the ‘60s, neuroleptics have started to be used on TS and became the most efficient medications. Most used neuroleptics which have been reported in controlled studies or case reports are haloperidol, pimozide, sulphiride, risperidone, olanzapine and ziprazidone.1 Since then, typical neuroleptics have been decreasingly prescribed due to their side-effects. We will present a resistant TS case that responded with aripiprazol, whose mechanism of action differs from both typical and atypical antipsychotics.2

Up to now, there is no publications about aripiprazol on TS. P., 20 years old, male, single, student, born at the countryside of the state of São Paulo and living at the state’s capital, has had his first multiple motor and vocal tics since the age of five. These tics have increasingly worsened causing much suffering for the patient and his family. Additionally, the patient showed obsessive-compulsive symptoms, besides major depressive episode, separation anxiety and panic with agoraphobia. He has unsuccessfully undergone all conventional (haloperidol, pimozide, trifluoperazine, sulphiride, olanzapine, ziprazidone, clonidine, butalbital toxin) and alternative (pergolide, nicotine, clonazepam, reserpine) tic treatments without success. It was added aripiprazol (15 mg/day) to the previous scheme a (sertraline + olanzapine, the latter gradually withdrawn) with tic improvement. Improvement was observed since the second week onwards using the medication and has persisted after three months of continuous treatment with 15 mg/day. The floating nature of tics hampers to assess if the improvement occurred due to the medication or to a remission phase of the disease proper. However, vocal tics, always extremely resistant to pharmacological treatment, decreased significantly, along with the motor tics, when aripiprazol was introduced.

In the current model about the pathogenesis of TS which involve cortical-subcortical circuits, it is believed that the increase in the dopaminergic stimulation in the striatal region implies higher release of glutamate in the thalamic-cortical projections, leading to release of involuntary movements.3-4

Aripiprazol has been described as a stabilizer of the dopamin-serotonin system. Its suggested mechanism of action is the partial agonism on D2 receptors, as it binds more to D2 G-protein bound receptors than to those which are not.2 The affinity of the drug for D2 is 4- to 20 times lower than that of haloperidol, chlorpromazine or other typical antipsychotics.5 Besides, it shows a partial agonist activity on 5HT1A receptors and antagonism on 5HT2A receptors. Most neocortex 5HT1A receptors are situated in glutamatergic pyramidal neurons. These receptors have an inhibitory action, which would reduce the excitatory glutamatergic output. It is believed that part of the control of tics would stem from this control in the glutamatergic projection pathways.

Aripiprazol, therefore, with a profile of side-effects characterized by lower weight gain, lower sedation, absence of prolactin levels elevation and of widening of QT space of electrocardiogram compared to other antipsychotics, becomes an interesting option for TS cases which do not respond to conventional therapies. It has, however, a high cost and needs official support to allow the poorest layers of the population to benefit from its effects. Controlled studies comparing aripiprazol to the conventional treatments for TS are needed.

Ana G Hounie, Maria Alice De Mathis,
Aline S Sampaio and Marcos T Mercadante

References

Current status of psychiatric residence in the center-western region

Dear Editor,

In the Center-Western region, Mato Grosso do Sul was one of the pioneer states to create medical residences in Psychiatry. The first one started its activities in 1992, at Campo Grande’s Santa Casa, and has been uninterruptedly functioning for 12 years, offering, currently, two positions. One decade after (2002), it was created a residence at the University Hospital of the Federal University of Mato Grosso do Sul, which has currently 01 place. We may highlight that both services are accredited by MEC (Brazil’s Secretary of Education)1 and have formed 32 psychiatrists since their beginning up to December 2003.

The importance of more residences in the Center-Western region stems from the situation of lack of specialists, mainly outside the great urban centers, which has been diagnosed long time ago. The number of psychiatrists in Brazil, according to estimations by ABP, cited by Torello,2 is nearly six thousands, and he highlights that university institutions are scarce and geographically concentrated. The Northern and the Center-Western regions represent this trend, as in the former there is no psychiatric residency while in the latter there are psychiatric residences only at Campo Grande (2), Goiânia (1) and Brasília (3), and in these six institutions only 14 psychiatrists graduate yearly,1 whereas the region’s population reaches more than 11 million inhabitants.2 Only the Psychiatric Institute of USP4 forms yearly 15 psychiatrists!

Regarding the services’ quality, in Mato Grosso do Sul from 1992 up to 2002, 28 physicians have concluded their residence or specialization. Of these, 25 took the exam to obtain the Specialist Degree at ABP and 22 (88%) have been approved. We believe that